EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A Case Report From the AGMT mCRC Registry

Iason Theodorou, Ronald Heregger, Richard Greil, Lukas Weiss, Florian Huemer

Clinical Colorectal Cancer · 2026-06 · 25 (2) · 297-301

DOI: 10.1016/j.clcc.2026.01.004 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Colorectal Cancer, 2026-06. Verfasst von Iason Theodorou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus …. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharma AG, Servier, Amgen Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Micro-Abstract Encorafenib+cetuximab combined with chemotherapy is the new palliative 1L treatment standard in BRAF V600E-mutant, MSS mCRC. However, the disease often proves refractory to subsequent systemic therapy. In this case report, we describe about the rapid and durable clinical and radiographic response upon encorafenib+cetuximab re-challenge combined with nivolumab, supporting ongoing phase II clinical trials exploring the efficacy of re-challenge strategies.

Schlagwörter

Stichwörter der Autor:innen

BRAF V600E mutationImmune-checkpoint inhibitorMMRpMSSMicrosatellite stable

Autor:innen und Institutionen

  • Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.
  • Austrian Group of Medical Tumor Therapy (AGMT) Study Group, Vienna, Austria.
  • Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; Austrian Group of Medi…

Förderung

  • Takeda Pharma AG
  • Servier
  • Amgen Inc

Zitieren

APA

Theodorou, I., Heregger, R., Greil, R., Weiss, L., & Huemer, F. (2026). Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A Case Report From the AGMT mCRC Registry. Clinical Colorectal Cancer, 25(2), 297-301. https://doi.org/10.1016/j.clcc.2026.01.004

Vancouver

Theodorou I, Heregger R, Greil R, Weiss L, Huemer F. Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A Case Report From the AGMT mCRC Registry. Clinical Colorectal Cancer. 2026;25(2):297-301. doi:10.1016/j.clcc.2026.01.004

BibTeX
@article{Theodorou2026,
  author = {Theodorou, Iason and Heregger, Ronald and Greil, Richard and Weiss, Lukas and Huemer, Florian},
  title = {Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A Case Report From the AGMT mCRC Registry},
  journal = {Clinical Colorectal Cancer},
  year = {2026},
  volume = {25},
  number = {2},
  pages = {297--301},
  doi = {10.1016/j.clcc.2026.01.004}
}
Kostenlos starten →